Day: March 27, 2025

Iridex Reports Fourth Quarter and Full Year 2024 Financial Results

Written by Customer Service on March 27, 2025. Posted in Earnings Releases And Operating Results.

MOUNTAIN VIEW, Calif., March 27, 2025 (GLOBE NEWSWIRE) — Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and full year ended December 28, 2024. Fourth Quarter 2024 Results & Recent HighlightsAchieved positive adjusted EBITDA in the fourth quarter of 2024 Successfully implemented previously announced cost reduction program, resulting in operating expenses of $6.1 million, a 24% reduction compared to $8.0 million in the prior year period Generated total revenue of $12.7 million, compared to $12.5 million in the prior year quarter Cyclo G6® product family revenue in the fourth quarter reached $3.3 million, compared...

Barfresh Provides Fourth Quarter and Full Year 2024 Results and Business Update

Written by Customer Service on March 27, 2025. Posted in Earnings Releases And Operating Results.

Company Achieves Highest Fiscal Year Revenue in Company History Revenue of $10.7 Million, Gross Margin of 34% and Adjusted Gross Margin of 37% for Fiscal Year 2024 Pop & Go™ 100% Juice Freeze Pops Launched with Initial Revenue Generation in Fourth Quarter 2024 Company Raises $3 Million in Profitable Growth Financing; Financing to Accelerate Manufacturing and Market Expansion Company Expects Record Revenue for Fiscal Year 2025 of $14.5 Million to $16.6 Million LOS ANGELES, March 27, 2025 (GLOBE NEWSWIRE) — Barfresh Food Group Inc. (the “Company” or “Barfresh”) (Nasdaq: BRFH), a provider of frozen, ready-to-blend and ready-to-drink beverages, is providing a business update for the full year ended December 31, 2024. Management Comments Riccardo Delle Coste, the Company’s Chief Executive Officer, stated, “Our team delivered...

Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Written by Customer Service on March 27, 2025. Posted in Earnings Releases And Operating Results.

– Successful End-of-Phase 2 Meeting with FDA Results in Alignment on Phase 3 Plans for CLS-AX in Wet AMD – – Asia-Pacific Partner’s New Drug Application for ARCATUS® (XIPERE®) for Uveitic Macular Edema Accepted for Regulatory Review in China – – Multiple Medical Meeting Presentations Highlight Potential Advantages and Key Differentiators of Suprachoroidal Drug Delivery Utilizing Clearside’s SCS Microinjector® – – Management to Host Webcast and Conference Call Today at 4:30 P.M. ET – ALPHARETTA, Ga., March 27, 2025 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today announced financial results for the fourth quarter and year ended December...

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Written by Customer Service on March 27, 2025. Posted in Earnings Releases And Operating Results.

Expect Topline Phase 2 data for NDV-01 for high-grade non-muscle invasive bladder cancer (HG-NMIBC), to be presented at AUA 2025 in April Advancing novel neurosteroid, sepranolone, towards Phase 2b study in Tourette syndrome with plans for evaluation in other compulsion-related disorders, including Prader-Willi Syndrome Cash balance of $44.8 million as of December 31 2024 Management hosting conference call and webcast today at 4:30 PM ET CORAL GABLES, Fla., March 27, 2025 (GLOBE NEWSWIRE) — Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechnology company, today provided a corporate update and announced preliminary and unaudited financial results for the fourth quarter and full year ended December 31, 2024. The Company’s conference call, planned for today, Thursday, March 27th, at 4:30...

zSpace Reports Fourth Quarter and Full Year 2024 Financial Results

Written by Customer Service on March 27, 2025. Posted in Earnings Releases And Operating Results.

SAN JOSE, Calif., March 27, 2025 (GLOBE NEWSWIRE) — zSpace (NASDAQ: ZSPC) (“zSpace” or the “Company”), a leader in augmented and virtual reality solutions for education, is announcing its financial results for the three and twelve months ended December 31, 2024. “We are thrilled to be announcing our first quarter as a public company,” said Paul Kellenberger, CEO of zSpace. “Throughout 2024, we achieved significant milestones, including our largest customer win to date with St. Louis Public Schools and the expansion of our Career Readiness Solution, featuring our innovative AI Career Coach. “While we received IPO proceeds in early December, the late-quarter timing limited our ability to fulfill orders before year-end. As a result, we closed 2024 with $9.2 million in backlog, reflecting strong demand heading into 2025. With growing...

Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Written by Customer Service on March 27, 2025. Posted in Earnings Releases And Operating Results.

The recent $15 million financing accelerates development of REYOBIQ™ and launch of CNSide™ HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the fourth quarter and full year ended December 31, 2024, and provides an overview of recent and upcoming business highlights. “Over the last twelve months, Plus has reported very promising safety and efficacy data for our lead drug REYOBIQ administered in our two most advanced CNS cancer programs,” said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. “The recently raised capital, coupled with existing grant...

Better Choice Company Announces Fourth Quarter and Full Year 2024 Financial Results

Written by Customer Service on March 27, 2025. Posted in Earnings Releases And Operating Results.

Fourth Quarter 2024 Revenue Growth of 26% Year-Over-Year to $7.2 million Fourth Quarter 2024 Loss per Share Improves 97% Year-Over-Year to $(0.50) Fourth Quarter 2024 Adjusted EBITDA Loss Improves 80% to $(0.7) million Year-Over-Year1 Full Year 2024 Loss per Share Improves 100% year-over-year to $(0.10) Full Year 2024 Adjusted EBITDA Loss Improves 78% year-over-year to $(1.9) million1 TAMPA, Fla., March 27, 2025 (GLOBE NEWSWIRE) — Better Choice Company Inc. (NYSE American: BTTR) (the “Company” or “Better Choice”), a pet health and wellness company, today announced its results for the fourth quarter and year ended December 31, 2024. “Our fourth quarter results built on the momentum we saw during the third quarter and exceeded our internal projections across all key financial metrics,” commented Chief Executive Officer, Kent...

Martina Completes Debt Conversion and Appointment of New Directors

Written by Customer Service on March 27, 2025. Posted in Public Companies.

TORONTO, March 27, 2025 (GLOBE NEWSWIRE) — Martina Minerals Corp. (“Martina” or the “Corporation”) is pleased to announce that it has closed the settlement of $320,705 of indebtedness through the issuance of an aggregate of 9,163,000 common shares of the Corporation (the “Shares”) at a deemed price of $0.035 per Share (the “Debt Settlement”). The indebtedness was owed to six (6) arm’s length parties. The Shares are subject to a statutory hold period expiring on July 27, 2025. In addition, Martina is also pleased to announce that the following individuals have been appointed to the board of directors upon the resignation of the previous directors: Dylan W.Z. Su – Mr. Su is a seasoned real estate developer with over a decade of experience. Since moving to Toronto in 2009, Mr. Su has established himself as a forward-thinking...

Banco Comercial Português, S.A. informs on Annual Report 2024

Written by Customer Service on March 27, 2025. Posted in Public Companies.

Banco Comercial Português, S.A. informs on Annual Report 2024Attachments000432-2024-12-31RABCP2024Vol1ENVolume 2_RS2024_EN

Hermès International: Availability of the 2024 Universal Registration Document

Written by Customer Service on March 27, 2025. Posted in Public Companies.

Paris, 27 March 20258:00 p.m. (Paris time) AVAILABILITY OF THE 2024 UNIVERSAL REGISTRATION DOCUMENTINCLUDING THE ANNUAL FINANCIAL REPORT Hermès International filed its 2024 Universal Registration Document with the Financial Markets Authority (AMF), on 27 March 2025, in ESEF format. It is available to the public under current regulatory conditions and may be found on finance.hermes.com (under “Investors section” > “Publications” and “Regulated information”) The universal registration document comprises:the annual activity report; the parent company and consolidated financial statements for 2024; the report on sustainability information; the Supervisory Board’s report on the corporate governance; a description of the share buyback programme prepared pursuant to Articles 241-2 and 241-3 of the General Regulation of the Financial...

Day: March 27, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals